<code id='54B0D2FA18'></code><style id='54B0D2FA18'></style>
    • <acronym id='54B0D2FA18'></acronym>
      <center id='54B0D2FA18'><center id='54B0D2FA18'><tfoot id='54B0D2FA18'></tfoot></center><abbr id='54B0D2FA18'><dir id='54B0D2FA18'><tfoot id='54B0D2FA18'></tfoot><noframes id='54B0D2FA18'>

    • <optgroup id='54B0D2FA18'><strike id='54B0D2FA18'><sup id='54B0D2FA18'></sup></strike><code id='54B0D2FA18'></code></optgroup>
        1. <b id='54B0D2FA18'><label id='54B0D2FA18'><select id='54B0D2FA18'><dt id='54B0D2FA18'><span id='54B0D2FA18'></span></dt></select></label></b><u id='54B0D2FA18'></u>
          <i id='54B0D2FA18'><strike id='54B0D2FA18'><tt id='54B0D2FA18'><pre id='54B0D2FA18'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:entertainment    Page View:2464
          Buildings like hospitals and banks on a web with people operating laptops and phones — health tech coverage from STAT
          Adobe

          For years, the playbook for many companies that wanted to market digital therapeutics was stupid simple: Sell it like a prescription drug.

          But just because it was simple didn’t mean it was going to work.

          advertisement

          The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated. Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. Even after hitting roadblock after roadblock, the company stuck to its original plan and ended up vaporizing over $400 million in investment before finally throwing in the towel.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more
          Surge in Apellis stock fueled by confidence in safety of its eye drug
          Surge in Apellis stock fueled by confidence in safety of its eye drug

          MollyFerguson/STATSharesofApellisPharmaceuticalsarerebounding,drivenbyagrowingbeliefamongsomeinvesto

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          BMS, looking to build heart drug business, turns to AI for diagnosis

          AdobeAsBristolMyersSquibbworkstobuilditstreatmentforaheartconditionthatcancausedifficultybreathingin